

2025 INTERIM RESULTS

SMOORE INTERNATIONAL HOLDINGS LIMITED 思摩爾國際控股有限公司

(於開曼群島註冊成立的有限公司) (Incorporated in the Cayman islands with limited liability)

股份代號Stock Code: 6969

Contents

1 Key Financials

02 Financial Overview

Business Overview

04 Strategies



Key Financials of 2025 Interim Results



RMB million	2024 H1 ¹	2025 H1	Changes
Revenue	5,084	6,013	18.3%
Gross profit	1,924	2,244	16.6%
- Gross margin (%)	37.8%	37.3%	-0.5pp
R&D expenses	760	723	-4.9%
- % of total revenue	15.0%	12.0%	-3.0pp
Distribution and selling expenses	375	491	31.2%
- % of total revenue	7.4%	8.2%	+0.8pp
Administrative expense	339	610	79.7%
- % of total revenue	6.7%	10.1%	+3. <i>4</i> pp
Profit before tax	812	699	-13.9%
Net profit	683	492	-28.0%
- Net profit margin (%)	13.4%	8.2%	-5.2pp
Adjusted net profit ²	753	737	-2.1%
- Adjusted net profit margin (%)	14.8%	12.3%	-2.5pp
Dividend per share (HK\$ cents)	5.0	20.0	
Dividend payout ratio	38.7%	225.1%	

^{1:} Technical service revenue has been included in revenue starting from the 2024 Annual Report, and the comparable financial data for the six months ended 30 June, 2024 have been reclassified for presentation to ensure the comparability of financial data

 $^{2:} The \ adjusted \ net \ profit for \ the \ period \ added \ back \ the \ share-based \ payment \ expenses \ related \ to \ share \ option \ scheme \ and \ share \ award \ scheme \ and \ share-based \ payment \ expenses \ related \ to \ share \ option \ scheme \ and \ share \ award \ scheme \ award \ scheme$

Delivered What We Said – Building Momentum towards Future Growth





) What We Said at Year Beginning

 Recovery trend, supported by strengthened legal enforcement and launch of innovative compliant products

 Support strategic customer in launching new product in mid-year

 Inhalation therapy related R&D and beauty atomization business are progressing as planned



✓ Intensified legal enforcement and regulatory changes observed

Increased market share through new clients and compliant products



 ✓ New HNB product pilot launched in Sendai, Japan in June 2025



√ Advanced as original planned




What We Delivered in 2025 H1





Revenue growth further recovered in 25H1

Healthy growth by segments and by regions




^{1:} Technical service revenue has been included in revenue starting from the 2024 Annual Report, and the comparable financial data have been reclassified for presentation to ensure the comparability of financial data

^{2:} Revenue by regions is categorized by customers' places of incorporation after considering trans-shipment



Robust growth mainly driven by the recovery of electronic vaping



EU and Others: +38.0%

Key drivers







- ✓ Significant market opportunities brought by disposable ban in UK and major countries in EU
- Introduced multiple innovative and compliant product solutions aimed at delivering consumers unique and diverse flavor experiences
- Positive customer feedback, leading to strong order growth

U.S Markets: +1.5%

Key drivers







✓ Atomization products for special purposes under recovering

✓ Encouraging trend of intensified

non-compliant products

enforcement actions by the regulators


✓ However, market is still dominated by



✓ Inhalation therapy milestones on track




Strong growth momentum continued






Consistent emphasize on R&D to sustain our long-term development

R&D Expense by Segments




Key Milestones





Distribution and Marketing Expense

Administrative Expense



- Further expand into new markets and promote new products, especially self-branded vaping products (i.e. VAPORESSO)
- Non-cash share-based payment expenses partially charged to administrative expenses



Business Overview





A Global Leader in Atomization Technology								
Business Segment			Business Model	Target Market				
Core Business		Open-system		Self-branded	US, EU, and other markets			
	Nicotine Delivery System	Closed-system	PILLY IN THE PILLY	Primarily 2B	Global			
		Heat-not-burn		2B	EU and other markets			
	Atomization Products for Special Purpose			2B	US-Focused			
Emerging Business	Inhalation Therapy (Transpire Bio)			Self-branded+2B	US & EU			
	Beauty Atomization (MOYAL)			2B + 2C Self-branded	China-Focused			

03.1
Core Business



- Innovating compliant products with a user-centric approach
- ☐ Enhancing marketing digitalization, sales localization, and terminal store monitoring to continuously gain larger market share

1

Leading Brand Positioning

Upgraded versions of platform products driving increased market share for VAPORESSO in key markets

2

Accurate User Insights

- Self-developed data system
- Marketing digitalization
- · Sales localization
- Terminal store monitoring

3

Localized Operations

- Expanding sales channel coverage in key markets
- Improving product on-shelf availability

)-

Close Partnerships with Key Distributors

 Enabling swift responses to market changes







Crossed Categories -








- The major markets have banned disposable vaping products
- Compliant alternatives catering to consumer demands and generating robust revenue recovery







- □ U.S. market remains dominated by non-compliant products
 As a compliant player, SMOORE's U.S. vaping business is still under pressure
- U.S. joint multi-agency regulatory enforcement on non-compliant products gained steam Compliant market is gradually recovering as observed

State government enforcement Joint
enforcement by
federal-level
agencies

More Than \$7 Million Worth of Illegal E-

Cigarettes Seized in Federal Operation
Action is latest interagency collaboration to curb illegal distribution of e-cigarettes
CBP and FDA seize nearly \$34 million of illegal E-Cigarettes

The export volume to the U.S. has plummeted

Shelves empty as Utah's flavored vape juice ban goes into effect



Auring joint operation

Release Date: Thi, 05.22/2025

CHICAGO. U.S. Customs and Binder Protection, in collaborate too million wink of unanchionade or cigarette products in Check too million wink of unanchionade or cigarette products in Check proved linguist of cigarettes producing the customs.

During this operation, the season uncovered shipments of varieties or cigarettes products, allowed all of shipment of the collection of the collect



February 2025

New York State sued **13** vape manufacturers, distributors, and retailers

March 2025


Utah had already restricted the sale of flavored vape products

January 2025

Seized more than **628,000** unauthorized vaping Valued at more than **\$7 million**

May 2025

Seized nearly **2 million** unauthorized vaping Valued of nearly **\$34 million**



June 2025

The **export trade volume** of vaping products to the U.S. experienced a **sharp decline**¹

a month-on-month drop of **48%**

a year-on-year plunge of **66%**



- Possessing multi-technology platforms
- 2 Offering comprehensive total solutions to address user pain points
- Successfully assisting a strategic business customer to launch its premium HNB products in key markets in 2025





Emerging Business



Still in the Incubation Phase with Steady Progress as Planned



Pipeline Products and Technology

✓ Continuous R&D for proprietary drug-device combination products for asthma, COPD and pulmonary fibrosis





US R&D Center

- Established an inhalation center of excellence near Miami, Florida
- Full capabilities to develop dry powder inhaler and soft mist inhaler products







Manufacturing Capabilities

 Collaborated closely with world-leading contract development and manufacturing organizations (CDMOs)





Delivering Skincare Solutions with Dual Business Model



Revenue **+2,595.2%** yoy

User base has grown to exceed ten thousand

Home-use (2C)

Superconducting Gun + Superconducting Cannon

Online:

 Mainstream social media platforms

Offline:

· High-end stores

Integrating advanced beauty devices with selfdeveloped high-performance beauty essence

 Atomized Transdermal Delivery: The Next Evolution in Skincare Absorption



Beauty Institutions (2B)

Fog Light Therapy Device

Offline:

- National beauty institutions
- Public hospital

Non-Invasive Cosmetic Treatment: Collagen Infusion Therapy for Superficial Dermal Rejuvenation

- Advanced Atomization Technology: Precise Particle Sizing for Optimal Skin Crevice Penetration
- Targeted Transdermal Delivery: Energy-Modulated Layered Absorption Enhancement
- Class II Medical Device Certification










Cultivating a Comprehensive Atomization Ecosystem Built on Science and Technology



2023 2025 2030



For more information about the Company,
please follow our WeChat public account
"思摩尔科技" and "思摩尔国际投资者关系"

Please follow us on X: @SMOORE_IR

Investor Relations Contact ir@smooreholdings.com

Investor Relations Consultants smoore@christensencomms.com



Atomization Makes Life Better